Multiple Myeloma presents a notoriously difficult landscape for life sciences firms, where rapid shifts in treatment protocols often leave traditional market research obsolete before it is even published. Medisights addressed this by deploying purpose-built AI agents capable of conducting humanized, clinical-grade interviews. These agents maintained active, 45-to-60-minute conversations with specialists, uncovering specific barriers to CAR-T adoption that manual research methods frequently miss.
In section Releases
Medisights deploys AI agents to accelerate Multiple Myeloma research
By replacing months-long traditional market studies with adaptive AI moderators, Medisights has demonstrated a new method for capturing near real-time intelligence in complex oncology. The platform successfully engaged specialists in hour-long dialogues, mapping CAR-T referral pathways and identifying critical gaps in community oncologist education.
The study identified that insurance authorization remains a primary hurdle, while a significant knowledge gap persists among community oncologists regarding the distinction between in vivo CAR-T and off-the-shelf ex vivo products. According to Frank Seo, CEO of Medisights, the ability to map these regional referral patterns in real-time provides commercial teams with a level of visibility previously unattainable. By anchoring AI-gathered insights to clinical benchmarks like MRD negativity rates and overall survival, the platform aims to replace static reporting with a verifiable, continuous data layer. This approach allows firms to test messaging and address unmet needs through what the company describes as Digital Doctor Twins, ensuring compliance while navigating the complexities of modern therapeutic markets.
Comments (0)
No comments yet. Be the first!